SCHEMBL5474606

SCHEMBL5474606

FC(F)(F)COc1ccc(OCC(F)(F)F)c(-c2ccnc(NCc3ccccc3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
TP53 P04637 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
CDC7 O00311 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MAPK13 O15264 1/20 0.41
RAF1 P04049 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5477980 0.85 ALDH1A1 (0.43) SMN1; SMN2KDM4EALDH1A1POLBHPGD
SCHEMBL5471303 0.84 SYK (0.43) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL5472845 0.82 NPSR1 (0.46) KDM4EALDH1A1MEN1HPGDKMT2A
SCHEMBL5470861 0.80 NPSR1 (0.58) MAPTSMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL5464087 0.80 DYRK1B (0.42) MAPTSMN1; SMN2KDM4EALDH1A1POLB
SCHEMBL5472425 0.78 MAPT (0.44) MAPTKDM4EALDH1A1CYP1A2CYP2C9
SCHEMBL5476994 0.78 CYP17A1 (0.47) SMN1; SMN2KDM4EALDH1A1MEN1POLB
SCHEMBL5465680 0.78 CYP1A2 (0.49) SMN1; SMN2KDM4EALDH1A1POLBCDC7
SCHEMBL5467291 0.76 CCNT1 (0.44) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL5470760 0.76 KDM4E (0.42) MAPTSMN1; SMN2KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US claimed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP claimed
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR MAPT 4503/4885TP53 4158/4885SMN1; SMN2 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.